VivoSeq
Ophthalmology

Strabismus

33

Pipeline Programs

6

Active Trials

10

Companies Involved

Strabismus is a moderately active landscape with 33 programs across 10 companies. The most active players are Vitae Pharmaceuticals Inc., an Allergan affiliate, GSK, Avyxa. 8 therapies are approved with 3 more in late-stage development.

Pipeline Metrics

Competitive Density

54/100

Pipeline Velocity

15/100

Mech. Concentration

24/100

Completion Rate

100/100

Attrition Rate

0/100

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Programs by Phase

Trial Status

37

clinical trials

Completed24 · 65%
Unknown status7 · 19%
Not yet recruiting5 · 14%
Recruiting1 · 3%

Trial Activity

37 trials

Botulinum Toxin for Strabismus Treatment
Not yet recruiting·FFoundation University Islamabad·N/A·NCT07180394·127 enrolled
Botulinum Toxin A vs Strabismus Surgery for Esotropia
Not yet recruiting·JJaeb Center for Health Research·Phase 3·NCT07470164·244 enrolled
Low Flow Anesthesia in Children Undergoing Strabismus Surgery
Not yet recruiting··Phase 4·NCT06560268·150 enrolled
Pain After Strabismus Surgery
Not yet recruiting··Phase 2·NCT06689943·80 enrolled
Page 1 of 3

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)